Andras Perl received his M.D. and Ph.D. degrees from Semmelweis University in Budapest, Hungary. He was trained as a Resident at the Second Department of Internal Medicine at Semmelweis and as a Fellow at the University of Rochester. He held faculty positions at Semmelweis, the University of Rochester, and SUNY/Roswell Park Cancer Institute. He has been a Professor of Medicine, Microbiology, and Immunology since 1997, Chief of Rheumatology since 2001, and Codirector of the M.D./Ph.D. Program since 2003 at the SUNY Upstate Medical University College of Medicine In Syracuse, New York, USA. His research has been focused on interactions of viruses and the host genome and signaling pathways that underlie T-cell dysfunction in lupus and models of autoimmunity. His laboratory cloned the HRES-1/Rab4 gene and mapped its lupus-linked genomic haplotypes at chromosome 1q42. He detected and cloned the human transaldolase (TAL) gene and identified it as a controller of the pentose phosphate pathway, glutathione metabolism, and mitochondrial hyperpolarization (MHP), a novel checkpoint of T-cell activation and apoptosis. Lupus T cells exhibit MHP and ATP depletion which underlie in abnormal activation and death signaling. He developed TAL knock-out mice which have cell type-specific mitochondrial dysfunction and model human TAL deficiency. His laboratory has published over 100 peer-reviewed papers, authored chapters in immunology and rheumatology textbooks, trained over 30 Ph.D. students and postdoctoral fellows, and received funding from the National Institutes of Health, the National Multiple Sclerosis Society, the Arthritis Foundation, the American Lupus Society, and the Alliance for Lupus Research. He was listed among the Best Doctors in Central New York and Best Doctors in America in 2007 and 2008.
Biography Updated on 16 March 2009